ALKS: Alkermes plc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 1 sales totaling $83K in the last 180 days.
Insider sales
| Trade date | Insider | Role | Value | 10b5-1 plan |
|---|---|---|---|---|
| 2026-10-02 | Gaffin David Joseph | Officer | $83K | yes |
Clinical trial readouts
7 Phase 2 or 3 trials by Alkermes plc. with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2026-09 (est.) | OLZ/SAM | Schizophrenia | Phase 3 | 220 | Recruiting | NCT05303064 |
| 2026-11 (est.) | ALKS 2680 | Idiopathic Hypersomnia | Phase 2 | 126 | Enrollment complete | NCT06843590 |
| 2027-05 (est.) | ALKS 2680 Dose 1 | Narcolepsy Type 1 | Phase 3 | 150 | Recruiting | NCT07455383 |
| 2027-05 (est.) | ALKS 2680 Dose 1 | Narcolepsy Type 2 | Phase 3 | 176 | Recruiting | NCT07502443 |
| 2027-06 (est.) | ALKS 2680 Dose 1 | Narcolepsy Type 1 | Phase 3 | 150 | Recruiting | NCT07540897 |
| 2027-07 (est.) | ALKS 7290 | Attention Deficit Disorder With Hyperactivity (ADHD) | Phase 2 | 312 | Recruiting | NCT07755410 |
| 2027-09 (est.) | OLZ/SAM | Bipolar I Disorder | Phase 3 | 236 | Enrolling by invitation | NCT04987229 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.